Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.70 |
| ▸ | CNR1 | P21554 | 1/20 | 0.70 |
| ▸ | DRD4 | P21917 | 1/20 | 0.70 |
| ▸ | ACHE | P22303 | 1/20 | 0.70 |
| ▸ | HRH2 | P25021 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | HTR2C | P28335 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | SCN1A | P35498 | 1/20 | 0.70 |
| ▸ | HTR2B | P41595 | 1/20 | 0.70 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11503340 | 0.94 | LMNA (0.63) | LMNASCN5ACYP1A2MAOACNR1 | |
| SCHEMBL22438952 | 0.94 | LMNA (0.63) | LMNASCN5ACYP1A2MAOACNR1 | |
| SCHEMBL28018634 | 0.94 | LMNA (0.63) | LMNASCN5ACYP1A2MAOACNR1 | |
| SCHEMBL11334918 | 0.94 | LMNA (0.63) | LMNASCN5ACYP1A2MAOACNR1 | |
| SCHEMBL13444627 | 0.93 | LMNA (0.61) | LMNASCN5ACYP1A2MAOACNR1 | |
| SCHEMBL9307380 | 0.91 | LMNA (0.60) | LMNASCN5ACYP1A2MAOACNR1 | |
| SCHEMBL7101006 | 0.90 | MAPT (0.60) | LMNASCN5ACYP1A2MAOACNR1 | |
| SCHEMBL29143435 | 0.89 | LMNA (0.77) | LMNASCN5ACYP1A2MAOACNR1 | |
| Ethyl Benzoate SCHEMBL23495786 | 0.89 | SMN1; SMN2 (0.60) | LMNASCN5ACYP1A2MAOACNR1 | |
| SCHEMBL11191100 | 0.87 | LMNA (0.56) | LMNASCN5ACYP1A2MAOACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115466190-B | Preparation method and application of tetracaine | 浙江孚诺医药股份有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-117233307-A | Detection method and application of tetracaine hydrochloride related substances in compound tetracaine cream | 南京逐陆医药科技有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-115466190-A | Preparation method and application of tetracaine | 浙江孚诺医药股份有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-109970583-A | A kind of production method of P-butylaminobenzoic acid ethyl ester | 北京旋光普利生物医药科技开发有限公司 | 2019-07-05 | — | — | CN | claimed |
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-07-03 | — | — | US | claimed |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-07-03 | — | — | US | claimed |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | claimed |
| US-20030114454-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-19 | — | — | US | claimed |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-12 | — | — | US | claimed |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-05 | — | — | US | claimed |
| US-20030100559-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-29 | — | — | US | claimed |
| US-20030096818-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-22 | — | — | US | claimed |
| US-20030087905-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-08 | — | — | US | claimed |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-01 | — | — | US | claimed |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-02-13 | — | — | US | claimed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| CN-120121749-A | Method for detecting 18 local anesthetics in cosmetics | 苏州市药品检验检测研究中心（苏州市药品不良反应监测中心） | 2025-06-10 | — | — | CN | disclosed |
| CN-119390597-A | Preparation method of tetracaine crystal form | 长沙晶易医药科技股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-115466190-B | Preparation method and application of tetracaine | 浙江孚诺医药股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-117368377-A | Method for detecting methylparaben and propylparaben in lidocaine tetracaine cream | 上海朝晖药业有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117233307-A | Detection method and application of tetracaine hydrochloride related substances in compound tetracaine cream | 南京逐陆医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116444387-A | Preparation method of high-purity tetracaine bulk drug | 江苏万高药业股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-115466190-A | Preparation method and application of tetracaine | 浙江孚诺医药股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-115466190-A | Preparation method and application of tetracaine | 浙江孚诺医药股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-113649024-A | Preparation of catalyst for producing ethyl p-butylaminobenzoate | 北京旋光普利生物医药科技开发有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113649024-A | Preparation of catalyst for producing ethyl p-butylaminobenzoate | 北京旋光普利生物医药科技开发有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113649024-A | Preparation of catalyst for producing ethyl p-butylaminobenzoate | 北京旋光普利生物医药科技开发有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-10947344-B2 | Route for the synthesis of statistical, aliphatic-aromatic copolyamides, and the resulting statistical, aliphatic-aromatic copolyamides | UNIVERSITÉ DE BORDEAUX (FR) | 2021-03-16 | — | — | US | disclosed |
| US-20200369897-A1 | PHOTOCURABLE INK COMPOSITION AND METHOD FOR FORMING IMAGE | FUJIFILM CORPORATION (JP) | 2020-11-26 | — | — | US | disclosed |
| US-20190276604-A1 | NOVEL ROUTE FOR THE SYNTHESIS OF STATISTICAL, ALIPHATIC-AROMATIC COPOLYAMIDES, AND THE RESULTING STATISTICAL, ALIPHATIC-AROMATIC COPOLYAMIDES | UNIVERSITÉ DE BORDEAUX (FR) | 2019-09-12 | — | — | US | disclosed |
| CN-109970583-A | A kind of production method of P-butylaminobenzoic acid ethyl ester | 北京旋光普利生物医药科技开发有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-109970583-A | A kind of production method of P-butylaminobenzoic acid ethyl ester | 北京旋光普利生物医药科技开发有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-104837948-B | The pressure sensitive adhesive of thermal activation | 罗门哈斯公司 | 2017-08-08 | — | — | CN | disclosed |
| EP-2909279-B1 | HEAT ACTIVATED PRESSURE SENSITIVE ADHESIVE | ROHM & HAAS (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9453148-B2 | Heat activated pressure sensitive adhesive | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150368521-A1 | HEAT ACTIVATED PRESSURE SENSITIVE ADHESIVE | ROHM AND HAAS COMPANY | 2015-12-24 | — | — | US | disclosed |
| EP-2909279-A1 | HEAT ACTIVATED PRESSURE SENSITIVE ADHESIVE | Rohm and Haas Company (US) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014093043-A1 | HEAT ACTIVATED PRESSURE SENSITIVE ADHESIVE | ROHM AND HAAS COMPANY (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-2476668-B1 | ANILINE COMPOUNDS | UBE INDUSTRIES (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-20120184747-A1 | ANILINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2476668-A1 | ANILINE COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| EP-1299381-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2002000649-A9 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| CN-1267431-C | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | CN | disclosed |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | US | disclosed |
| US-6919338-B2 | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase | ASTRAZENECA AB (SE) | 2005-07-19 | — | — | US | disclosed |
| US-6765023-B2 | SUCH AS 3-((3-(3-TRIFLUOROMETHOXYPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY) -PHENYL)METHYL) AMINO)-1,1,1-TRIFLUORO-2-PROPANOL FOR TREATING CARDIOVASCULAR DISORDERS AND DYSLIPIDEMIA | PFIZER, INC. | 2004-07-20 | — | — | US | disclosed |
| CN-1496364-A | Substituted quinazoline derivatives and their use as inhibitors | — | 2004-05-12 | — | — | CN | disclosed |
| US-6723753-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES. | PHARMACIA CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-6699898-B2 | METHOD OF TREATING CORONARY ARTERY DISEASE OR OTHER CETP-MEDIATED DISORDERS IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF ONE OF CLAIMS | PHARMACIA CORPORATION GLOBAL PATENT DEPARTMENT | 2004-03-02 | — | — | US | disclosed |
| US-6696435-B2 | FOR TREATING ATHEROSCLEROSIS, OTHER CORONARY ARTERY DISEASES; 3-((3-(3-TRIFLUOROMETHOXYPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY) -PHENYL)METHYL) AMINO)-1,1,1-TRIFLUORO-2-PROPANOL FOR EXAMPLE | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6696472-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6683099-B2 | FOR THERAPY OF ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6677353-B2 | CONTAINING A HALOALKYL GROUP: E.G., 3-((3-(3-TRIFLUOROMETHOXYPHENOXY) PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY)PHENYL)METHYL)AMINO)-1,1,1-TRIFLUORO-2-PROPANOL | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-6677375-B2 | TREATING CARDIOVASCULAR DISEASES | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-6677379-B2 | SUCH AS 3-((3-(3-TRIFLUOROMETHOXYPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY) -PHENYL)METHYL) AMINO)-1,1,1-TRIFLUORO-2-PROPANOL FOR TREATMENT OF CORONARY ARTERY DISEASE | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-07-03 | — | — | US | disclosed |
| US-6586433-B2 | Anticholesterol agents; antilipemic agents; cardiovascular disorders | PHARMACIA CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | disclosed |
| US-6583183-B2 | N-phenyl-N-fused-benzyl aminoalcohol derivatives, useful for treating atherosclerosis and other coronary artery diseases | PHARMACIA CORPORATION | 2003-06-24 | — | — | US | disclosed |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-12 | — | — | US | disclosed |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-05 | — | — | US | disclosed |
| US-20030100559-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-29 | — | — | US | disclosed |
| US-20030096818-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030087905-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-08 | — | — | US | disclosed |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-01 | — | — | US | disclosed |
| EP-1299381-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| US-20020183397-A1 | Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-12-05 | — | — | US | disclosed |
| US-6479552-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | G.D. SEARLE & CO. | 2002-11-12 | — | — | US | disclosed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | disclosed |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | disclosed |
| US-6476075-B1 | Use of substituted N, N-bis-benzyl aminoalcohol compounds inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-11-05 | — | — | US | disclosed |
| US-6462092-B1 | SUCH AS 3-((3-FLUOROPHENYL)-((3-(TRIFLUOROMETHYL)PHENYL)-METHYL)AMINO)-1,1,1 -TRIFLUORO-2-PROPANOL; CARDIOVASCULAR DISEASE, I.E. ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | G.D. SEARLE & CO. | 2002-10-08 | — | — | US | disclosed |
| US-6458803-B1 | COMPOSITIONS AND METHODS FOR TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES. PREFERRED TERTIARY-HETEROALKYLAMINE COMPOUNDS ARE SUBSTITUTED N-PHENYL-N-HETEROARALKYL AMINOALCOHOLS. A PREFERRED SPECIFIC | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6458849-B1 | METHOD OF TREATING OR PREVENTING A CEIP-MEDIATED DISORDER IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND FOR STROKES | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6458852-B1 | A METHOD OF TREATING OR PREVENTING A CETP-MEDIATED DISORDER IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6455519-B1 | TREATING ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-09-24 | — | — | US | disclosed |
| US-6451823-B1 | Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-09-17 | — | — | US | disclosed |
| US-6448295-B1 | TREATING CARDIOVASCULAR DISEASE; ATHEROSCLEROSIS, DYSLIPIDEMA HYPERCHOLESTEROLAEMIA; DECREASING CONCENTRATIONS OF LOW DENSITY LIPOPROTEIN AND RAISING LEVEL OF HIGH DENSITY LIPOPROTEIN | G.D. SEARLE & CO. | 2002-09-10 | — | — | US | disclosed |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-08-29 | — | — | US | disclosed |
| WO-2002000649-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| US-5352677-A | Antihyperlipidemic agents | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1994-10-04 | — | — | US | disclosed |
| EP-0407200-B1 | Cinnamamide derivatives | KANEGAFUCHI CHEMICAL IND (JP) | 1994-06-01 | — | — | EP | disclosed |
| US-5294643-A | Cinnamamide derivative | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI (JP) | 1994-03-15 | — | — | US | disclosed |
| US-5294624-A | Antiartheriosclerosis | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1994-03-15 | — | — | US | disclosed |
| EP-0407200-A1 | Cinnamamide derivatives | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-01-09 | — | — | EP | disclosed |
| EP-0190667-B1 | PROCESS FOR THE PREPARATION OF METHYL N-METHYLANTHRANILATE | National Starch and Chemical Corporation (US) | 1988-05-11 | — | — | EP | disclosed |
| EP-0190667-B1 | PROCESS FOR THE PREPARATION OF METHYL N-METHYLANTHRANILATE | National Starch and Chemical Corporation (US) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114454-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | LMNA 1614/4885SCN5A 3824/4885CYP1A2 1679/4885 |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | LMNA 1614/4885SCN5A 3824/4885CYP1A2 1679/4885 |
| US-20120184747-A1 | ANILINE COMPOUND | PTGER2, ADRB2, PTGER1 | LMNA 1385/4885SCN5A 723/4885CYP1A2 344/4885 |
| US-20020183397-A1 | Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | LMNA 744/4885SCN5A 3555/4885CYP1A2 2872/4885 |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | LMNA 1614/4885SCN5A 3824/4885CYP1A2 1679/4885 |
| US-20030096818-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | LMNA 1614/4885SCN5A 3824/4885CYP1A2 1679/4885 |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, LCAT, MTTP | LMNA 1157/4885SCN5A 3622/4885CYP1A2 2021/4885 |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | LMNA 1614/4885SCN5A 3824/4885CYP1A2 1679/4885 |
| US-20030087905-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | LMNA 1614/4885SCN5A 3824/4885CYP1A2 1679/4885 |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | LMNA 1614/4885SCN5A 3824/4885CYP1A2 1679/4885 |
| US-20030100559-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | LMNA 1614/4885SCN5A 3824/4885CYP1A2 1679/4885 |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | LMNA 1614/4885SCN5A 3824/4885CYP1A2 1679/4885 |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PCTP | LMNA 848/4885SCN5A 3526/4885CYP1A2 1488/4885 |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, PCTP, DBI | LMNA 1443/4885SCN5A 2398/4885CYP1A2 3905/4885 |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | LMNA 1297/4885SCN5A 2962/4885CYP1A2 3072/4885 |
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | LMNA 1614/4885SCN5A 3824/4885CYP1A2 1679/4885 |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKB, AURKC | LMNA 2963/4885SCN5A 1162/4885CYP1A2 2362/4885 |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKC, AURKB | LMNA 2697/4885SCN5A 980/4885CYP1A2 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.